Cargando…
A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844590/ https://www.ncbi.nlm.nih.gov/pubmed/29280761 http://dx.doi.org/10.1097/QAD.0000000000001730 |
_version_ | 1783305261590511616 |
---|---|
author | Rodríguez-Gallego, Esther Gómez, Josep Pacheco, Yolanda M. Peraire, Joaquim Viladés, Consuelo Beltrán-Debón, Raúl Mallol, Roger López-Dupla, Miguel Veloso, Sergi Alba, Verónica Blanco, Julià Cañellas, Nicolau Rull, Anna Leal, Manuel Correig, Xavier Domingo, Pere Vidal, Francesc |
author_facet | Rodríguez-Gallego, Esther Gómez, Josep Pacheco, Yolanda M. Peraire, Joaquim Viladés, Consuelo Beltrán-Debón, Raúl Mallol, Roger López-Dupla, Miguel Veloso, Sergi Alba, Verónica Blanco, Julià Cañellas, Nicolau Rull, Anna Leal, Manuel Correig, Xavier Domingo, Pere Vidal, Francesc |
author_sort | Rodríguez-Gallego, Esther |
collection | PubMed |
description | OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. DESIGN: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). METHODS: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4(+) T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. RESULTS: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. CONCLUSION: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role. |
format | Online Article Text |
id | pubmed-5844590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-58445902018-03-20 A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients Rodríguez-Gallego, Esther Gómez, Josep Pacheco, Yolanda M. Peraire, Joaquim Viladés, Consuelo Beltrán-Debón, Raúl Mallol, Roger López-Dupla, Miguel Veloso, Sergi Alba, Verónica Blanco, Julià Cañellas, Nicolau Rull, Anna Leal, Manuel Correig, Xavier Domingo, Pere Vidal, Francesc AIDS Basic Science OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. DESIGN: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). METHODS: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4(+) T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. RESULTS: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. CONCLUSION: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role. Lippincott Williams & Wilkins 2018-03-13 2018-03-07 /pmc/articles/PMC5844590/ /pubmed/29280761 http://dx.doi.org/10.1097/QAD.0000000000001730 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Basic Science Rodríguez-Gallego, Esther Gómez, Josep Pacheco, Yolanda M. Peraire, Joaquim Viladés, Consuelo Beltrán-Debón, Raúl Mallol, Roger López-Dupla, Miguel Veloso, Sergi Alba, Verónica Blanco, Julià Cañellas, Nicolau Rull, Anna Leal, Manuel Correig, Xavier Domingo, Pere Vidal, Francesc A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title | A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title_full | A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title_fullStr | A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title_full_unstemmed | A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title_short | A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients |
title_sort | baseline metabolomic signature is associated with immunological cd4(+) t-cell recovery after 36 months of antiretroviral therapy in hiv-infected patients |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844590/ https://www.ncbi.nlm.nih.gov/pubmed/29280761 http://dx.doi.org/10.1097/QAD.0000000000001730 |
work_keys_str_mv | AT rodriguezgallegoesther abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT gomezjosep abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT pachecoyolandam abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT perairejoaquim abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT viladesconsuelo abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT beltrandebonraul abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT mallolroger abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT lopezduplamiguel abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT velososergi abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT albaveronica abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT blancojulia abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT canellasnicolau abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT rullanna abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT lealmanuel abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT correigxavier abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT domingopere abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT vidalfrancesc abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT rodriguezgallegoesther baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT gomezjosep baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT pachecoyolandam baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT perairejoaquim baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT viladesconsuelo baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT beltrandebonraul baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT mallolroger baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT lopezduplamiguel baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT velososergi baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT albaveronica baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT blancojulia baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT canellasnicolau baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT rullanna baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT lealmanuel baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT correigxavier baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT domingopere baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients AT vidalfrancesc baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients |